Paul Stead

Biography

 PAUL STEAD joined Inovio Pharmaceuticals in October 2016 where he has responsibility for Business Development and Licensing. Prior to Inovio, Paul was Vice President of Business Development at Nimbus Therapeutics – a company developing novel therapies within metabolic and immunological diseases, and oncology. Paul was part of the core team that partnered Nimbus’ lead clinical stage program for the treatment of NASH and related disorders with Gilead Sciences in May 2016. Prior to joining Nimbus, Paul worked at GSK for over 20 years in a variety of roles including Senior Director - Worldwide Business Development, and Head of Natural Product Chemistry - Molecular Discovery Research. Paul obtained his Bachelor’s degree in Pharmacy from The University of Bath, and holds a PhD in Biochemistry from the University of Nottingham and an MBA from Lehigh University.

Research Interest

 metabolic and immunological diseases, and oncology